ClinicalTrials.gg
CompletedNCT00937521Updated Apr 7, 2015Results posted

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

A Phase 2 interventional study of Meningococcal B vaccine and Meningococcal B vaccine in Meningococcal Meningitis and Meningococcal Infections, sponsored by Novartis Vaccines. Completed at 38 sites in 5 countries. Open to participants aged 55 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-07.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,507
Allocation
Randomized
Ages
55 Days to 89 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningitis, Meningococcal.

Enrollment
2nd of 11
1,507 · median 250
Started
2009
with 1 other
Phase 2
3 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
4 of 11
Novartis Vaccines

Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, this one is the 2nd largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 2, and was the 2nd registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

1 of the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 55 Days to 89 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, or all of them as a file.
02

Study summary

This study is aimed at assessing the safety and immunogenicity of different doses and formulations of a new Novartis Meningococcal B Recombinant Vaccine.

03

Conditions studied

  • Meningococcal Meningitis
  • Meningococcal Infections

Keywords

  • Immunogenicity
  • Meningitis
  • Antibody
  • Infants
04

Who can participate

Ages eligible
55 Days to 89 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2-month old infants (55-89 days, inclusive), born after full term pregnancy, gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg
  • Available for all the visits scheduled in the study and for whom a parent/legal guardian is willing/able to comply with all protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Any meningococcal B or C vaccine administration
  • Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell), Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), and Pneumococcal antigens;
  • Any ascertained or suspected disease caused by N. meningitidis
  • Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis
  • History of severe allergic reaction after previous vaccinations
  • Recent significant acute or chronic infection
  • Oral or parenteral antibiotic treatment in the 7 days prior to the scheduled blood draw;
  • Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, disease, infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition)
  • Any impairment/alteration of the immune system resulting from (for example):

    • Receipt of any therapy at any time since birth
    • Receipt of immunostimulants at any time since birth
    • Use of systemic or chronic use of inhaled high-potency corticosteroids at any time since birth
  • Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation
  • Participation in another clinical trial
  • Family members and household members of research staff
  • History of seizure
  • Any to paracetamol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,507 participants (actual)

Study arms

  • Other
    1

    Vaccine candidate formulation I

    Biological: Meningococcal B vaccine

  • Other
    2

    Vaccine candidate formulation II

    Biological: Meningococcal B vaccine

  • Other
    3

    Vaccine candidate formulation III

    Biological: Meningococcal B vaccine

  • Other
    4

    Vaccine candidate formulation IV

    Biological: Meningococcal B vaccine

  • Other
    5

    Vaccine candidate formulation V

    Biological: Meningococcal B vaccine

  • Other
    6

    Vaccine candidate formulation VI

    Biological: Meningococcal B vaccine

  • Other
    7

    Control

    Biological: Control

  • Other
    8

    Vaccine candidate formulation I with antipyretic

    Biological: Meningococcal B vaccine with antipyretic

Interventions

06

What researchers measure

Primary outcomes

  1. Percentages of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:5 at 1 Month After Third Vaccination

    To assess the immunogenicity of seven different formulations of 4CMenB (groups I-VI and VIII) given to healthy infants at 2,3 and 4 months of age as measured by percentages of subjects with serum bactericidal activity (SBA) titer≥1:5 against 44/76-SL, 5/99 and NZ98/254 reference strains, at 1 month after the third vaccination.. The analysis was done on the Per Protocol Primary Population at one month after third injection.

    Time frame: At baseline (pre-vaccination) and 30 days after the third vaccination.

  2. Number of Subjects With Fever ≥ 38.5 °C (Rectal Temperature) Within 3 Days (Day 1-3) After First Vaccination

    To assess if any of six different formulations of vaccine groups (Group II to Group VI, Group VIII) reduced the incidence of fever \>=38.5C (rectal) occurring within three days (day 1-day3) following first vaccination. The analysis was done on the Safety Population.

    Time frame: Day 1 to day 3 after first vaccination.

Secondary outcomes

  1. Geometric Mean Bactericidal Titers (GMTs), One Month After Third and Booster Vaccination (Men B at 12 Months of Age)

    ToTo assess the immune response of seven different formulations of meningococcal multi-component recombinant, adsorbed vaccine (rMenB+OMV NZ or rMenB (no OMV)) in healthy toddlers as measured by SBA geometric mean titers (GMTs) at: 1. One month after third vaccination. 2. One month after booster vaccination (Men B at 12 months of age).

    Time frame: At baseline (pre-vaccination), 30 days after the third vaccination, at booster Baseline and at booster vaccination (12 months of age)

  2. Geometric Mean Bactericidal Titers,One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)

    To compare the antibody response of meningococcal multi-component recombinant, adsorbed vaccine (formulation I vs. formulation VIII) and of routine infant vaccine given with or without prophylactic administration of paracetamol medication in healthy toddlers.

    Time frame: At Baseline (pre-vaccination), at 30 days after the third vaccination, at booster Baseline, at 30 days

  3. Geometric Mean Ratios, One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)

    To compare the antibody response between meningococcal multi-component recombinant adsorbed vaccine (formulation I) and routine infant vaccine group along with meningococcal multi-component recombinant adsorbed vaccine with prophylactic administration of paracetamol medication as measured by Geometric Mean Ratios (GMRs).

    Time frame: After the third and the booster vaccination.

  4. Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (Pre-fourth Dose)

    To assess the persistence of bactericidal antibodies at 12 months of age after primary vaccination - three doses of one of the seven different formulations of rMenB+OMV NZ or rMenB (no OMV) (Group I-VI and VIII) and rMenB+OMV NZ with paracetamol medication.

    Time frame: 12 months (pre-fourth vaccination)

  5. Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (One Month-post Fourth Dose)

    To assess if any of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (groups I-VI and VIII) induced sufficient immune response when given to healthy toddlers at 12 months of age, as measured by percentage of subjects with SBA titer ≥ 1:5, at 1 month after the fourth vaccination.

    Time frame: 1 month after fourth vaccination

  6. Geometric Mean Bactericidal Titers, After Primary and Booster Vaccinations (Men B at 12 Months of Age)

    To assess the induction of immunological memory of three doses of meningococcal multi-component recombinant, adsorbed vaccine by comparing the serum bactericidal antibodies Geometric Mean Bactericidal Titers (GMTs) response in healthy toddlers administered the fourth dose at 12 months of age to the response in meningococcal B vaccine naive toddlers (Group VII) receiving the first dose of meningococcal multi-component recombinant, adsorbed vaccine at 12 months of age.

    Time frame: At 13 months

  7. Percentage of Subjects With hSBA ≥1:5, First Dose of Meningococcal B Vaccine (One Month After Booster)

    To assess the immune response of first dose of meningococcal multi-component recombinant, adsorbed vaccine given at 12 months of age to toddlers who previously received three doses of MenC-CRM197 vaccine as infants (group VII).

    Time frame: 1 month after booster

  8. Safety and Reactogenicity of Study Vaccines Within 7 Days After Second and Third Vaccination

    To assess if any of six different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (Group II to VI, Group VIII) reduced the incidence of fever ≥ 38.5ºC (rectal) occurring within 3 days (day 1-3) following second and third vaccination and 7 days (day 1-7) following each vaccination as compared to rMenB+OMV NZ (Group I).

    Time frame: Day 1 through day 7 after second and third vaccination.

  9. Number of Subjects With Solicited Local Reactions Within 7 Days (Day 1-7) After Each Vaccination

    To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited local reactions within 7 days (day 1-7) after each vaccination.

    Time frame: Day 1 through day 7 after each vaccination.

  10. Number of Subjects With Solicited Systemic Reactions Within 7 Days (Day 1-7) After Each Vaccination

    To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited systemic reactions within 7 days (day 1-7) after each vaccination.

    Time frame: Day 1 through day 7 after each vaccination.

  11. Number of Subjects With Unsolicited Adverse Events Within 7 Days (Day 1-7) After Each Vaccination

    To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting unsolicited Adverse Events (AEs), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period) within 7 days (day 1-7) after each vaccination.

    Time frame: Day 1 through day 7 after each vaccination.

  12. Number of Subjects With Severe Adverse Events and Adverse Events Necessitating a Medical Office or Emergency Room (ER) Visit and/or Resulting in Premature Withdrawal of the Subject From the Study, Throughout the Study Period.

    To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting Severe Adverse Events (SAEs) and Adverse Events (AEs) necessitating a medical office or Emergency Room (ER) visit and/or resulting in premature withdrawal of the subject from the study, throughout the study period.

    Time frame: Overall study period.

  13. Number of Subjects With Local and Systemic Reactions Within 7 Days (Day 1-7) After Second rMenB+OMV NZ Vaccination in MenC Group

    To assess the safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group VII) given at 12 and 13 months of age to toddlers who previously received three doses of Menjugate as infants.

    Time frame: Day 1 through day 7 at 13 months age.

07

Results

Posted Mar 4, 2015

Participant flow

Overall Study - Prior to Booster Dose
Participant flow — Overall Study - Prior to Booster Dose
MilestoneB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
Started188190192188191188186184
Premature withdrawal35613151
Completed185185186187188187181183
Not completed35613151
Withdrew: Adverse event00200010
Withdrew: Withdrawal by subject21301021
Withdrew: Lost to follow-up00110000
Withdrew: Inappropriate enrollment04002110
Withdrew: Protocol deviation10000010
Booster Phase
Participant flow — Booster Phase
MilestoneB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
Started155163169170168165165161
Premature withdrawal32535552
Completed152161164167163160160159
Not completed32535552
Withdrew: Adverse event00000010
Withdrew: Withdrawal by subject10010002
Withdrew: Lost to follow-up22424430
Withdrew: Administrative reason00101100
Withdrew: Protocol deviation00000010

Outcome measures

PrimaryPercentages of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:5 at 1 Month After Third Vaccination

To assess the immunogenicity of seven different formulations of 4CMenB (groups I-VI and VIII) given to healthy infants at 2,3 and 4 months of age as measured by percentages of subjects with serum bactericidal activity (SBA) titer≥1:5 against 44/76-SL, 5/99 and NZ98/254 reference strains, at 1 month after the third vaccination.. The analysis was done on the Per Protocol Primary Population at one month after third injection.

Time frame:
At baseline (pre-vaccination) and 30 days after the third vaccination.
Reported as:
Number · Percentages of Subjects
Percentages of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:5 at 1 Month After Third Vaccination
Percentages of SubjectsB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
44/76SLBaseline(N=166,171,168,170,169,168,168,166)5 (2 to 9)2 (0 to 5)4 (1 to 8)4 (2 to 8)4 (2 to 8)4 (2 to 8)2 (1 to 6)3 (1 to 7)
44/76-SL > 3rd(N=170,170,166,166,169,167,165,167)100 (98 to 100)99 (97 to 100)99 (97 to 100)100 (98 to 100)99 (97 to 100)99 (96 to 100)6 (3 to 11)100 (98 to 100)
5/99-Baseline (N=162,162,161,161,166,166,161,157)5 (2 to 9)3 (1 to 7)6 (3 to 10)4 (2 to 9)8 (5 to 14)4 (2 to 8)6 (3 to 10)4 (1 to 8)
5/99 > 3rd (N=165,167,161,166,165,161,159,160)99 (97 to 100)100 (98 to 100)99 (97 to 100)100 (98 to 100)100 (98 to 100)99 (97 to 100)3 (1 to 7)99 (97 to 100)
NZ98/254Baseline(N=170,174,171,174,171,173,171,1691 (0.015 to 3)0 (0 to 2)1 (0.015 to 3)1 (0.015 to 3)1 (0 to 4)1 (0 to 4)2 (0 to 5)1 (0.015 to 3)
NZ98/254 > 3rd (N=171,172,169,168,172,169,168,168)78 (71 to 84)67 (59 to 74)56 (48 to 64)1 (0.015 to 3)62 (54 to 69)81 (74 to 87)2 (0 to 5)74 (67 to 81)
SecondaryGeometric Mean Bactericidal Titers (GMTs), One Month After Third and Booster Vaccination (Men B at 12 Months of Age)

ToTo assess the immune response of seven different formulations of meningococcal multi-component recombinant, adsorbed vaccine (rMenB+OMV NZ or rMenB (no OMV)) in healthy toddlers as measured by SBA geometric mean titers (GMTs) at: 1. One month after third vaccination. 2. One month after booster vaccination (Men B at 12 months of age).

Time frame:
At baseline (pre-vaccination), 30 days after the third vaccination, at booster Baseline and at booster vaccination (12 months of age)
Reported as:
Geometric mean · Titers
Geometric Mean Bactericidal Titers (GMTs), One Month After Third and Booster Vaccination (Men B at 12 Months of Age)
TitersB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
44/76-SL Base(N=166,171,168,170,169,168,168,166)1.25 (1.14 to 1.37)1.12 (1.03 to 1.23)1.2 (1.1 to 1.32)1.19 (1.08 to 1.3)1.31 (1.19 to 1.43)1.2 (1.09 to 1.31)1.16 (1.09 to 1.25)1.18 (1.08 to 1.3)
44/76-SL > 3(N=170,170,166,166,169,167,165,167)101 (90 to 113)112 (101 to 126)113 (101 to 126)62 (56 to 70)71 (64 to 80)102 (92 to 114)1.24 (1.11 to 1.39)102 (91 to 115)
44/76-SL - Base Boost(N=69,78,74,78,71,71,74,70)4.94 (3.76 to 6.5)5.22 (4.03 to 6.76)5.72 (4.41 to 7.42)5.44 (4.19 to 7.06)3.96 (3.02 to 5.18)3.76 (2.87 to 4.94)1.15 (1.03 to 1.29)4.51 (3.43 to 5.95)
44/76-SL > Boost(N=65,73,70,75,76,71,75,63)120 (95 to 150)152 (122 to 189)118 (95 to 146)53 (43 to 66)99 (79 to 122)105 (84 to 131)12 (10 to 16)136 (107 to 172)
5/99-Baseline-(N=162,162,161,161,166,166,161,157)1.18 (1.07 to 1.3)1.09 (0.99 to 1.2)1.12 (1.02 to 1.23)1.13 (1.03 to 1.25)1.3 (1.18 to 1.43)1.16 (1.05 to 1.27)1.21 (1.09 to 1.34)1.07 (0.97 to 1.18)
5/99 > 3 (N=165,167,161,166,165,161,160)396 (348 to 450)503 (442 to 572)534 (469 to 608)389 (342 to 443)316 (278 to 360)371 (326 to 422)1.15 (1.03 to 1.29)455 (399 to 519)
5/99 Base Boost(N=71,76,80,72,77,78,70,71)69 (53 to 88)91 (71 to 116)111 (87 to 141)74 (57 to 94)54 (42 to 68)64 (50 to 81)1.11 (0.95 to 1.29)106 (82 to 136)
5/99 > Boost(N=73,77,79,72,76,74,69,76)1950 (1573 to 2417)1819 (1478 to 2238)2238 (1820 to 2751)730 (590 to 903)983 (801 to 1205)1321 (1074 to 1624)41 (29 to 57)2182 (1769 to 2691)
NZ98/254-BaselineN=170,174,171,174,171,173,171,1691.02 (0.99 to 1.06)1.02 (0.99 to 1.05)1.03 (1 to 1.06)1.04 (1 to 1.07)1.03 (1 to 1.06)1.04 (1.01 to 1.08)1.06 (1 to 1.13)1.02 (0.99 to 1.05)
1month after 3rd vaccN=171,172,169,172,169,169,16810 (8.59 to 12)7.81 (6.69 to 9.12)5.74 (4.92 to 6.71)1.05 (0.9 to 1.23)6.66 (5.71 to 7.77)11 (9.16 to 13)1.05 (1.01 to 1.1)8.48 (7.24 to 9.93)
NZ98/254 Bas Bst N=141,155,155,150,150,153,148,1431.6 (1.43 to 1.8)1.28 (1.15 to 1.43)1.23 (1.1 to 1.37)1.11 (0.99 to 1.24)1.35 (1.21 to 1.5)1.41 (1.26 to 1.57)1.03 (1 to 1.06)1.48 (1.32 to 1.66)
1month after boosterN=138,152,150,149,152,146,14020 (16 to 24)18 (15 to 22)11 (9.07 to 13)1.67 (1.38 to 2.03)14 (12 to 17)20 (16 to 24)2.2 (1.89 to 2.57)20 (17 to 25)
SecondaryGeometric Mean Bactericidal Titers,One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)

To compare the antibody response of meningococcal multi-component recombinant, adsorbed vaccine (formulation I vs. formulation VIII) and of routine infant vaccine given with or without prophylactic administration of paracetamol medication in healthy toddlers.

Time frame:
At Baseline (pre-vaccination), at 30 days after the third vaccination, at booster Baseline, at 30 days
Reported as:
Geometric mean · Titers
Geometric Mean Bactericidal Titers,One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)
TitersB+OMV (Group I)Par+B+OMV (Group VIII)
44/76-SL Strain - Baseline (N=166,166)1.25 (1.14 to 1.37)1.18 (1.08 to 1.3)
44/76-SL > 3rd (N=170,167)101 (90 to 113)102 (91 to 115)
44/76-SL Baseline booster (N=69,70)4.94 (3.76 to 6.5)4.51 (3.43 to 5.95)
44/76-SL > booster (N=65,63)120 (95 to 150)136 (107 to 172)
5/99 Strain - Baseline (N=162,157)1.18 (1.07 to 1.3)1.07 (0.97 to 1.18)
5/99 > 3rd (N=165,160)396 (348 to 450)455 (399 to 519)
5/99 Baseline booster (N=71,71)69 (53 to 88)106 (82 to 136)
5/99 > booser (N=73,76)1950 (1573 to 2417)2182 (1769 to 2691)
NZ98/254 Strain-Baseline (N=170,169)1.02 (0.99 to 1.06)1.02 (0.99 to 1.05)
NZ98/254 > 3rd (N=171,168)10 (8.59 to 12)8.48 (7.24 to 9.93)
NZ98/254 Baseline booster (N=141,143)1.6 (1.43 to 1.8)1.48 (1.32 to 1.66)
NZ98/254 > booster (N= 138, 140)20 (16 to 24)20 (17 to 25)
SecondaryGeometric Mean Ratios, One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)

To compare the antibody response between meningococcal multi-component recombinant adsorbed vaccine (formulation I) and routine infant vaccine group along with meningococcal multi-component recombinant adsorbed vaccine with prophylactic administration of paracetamol medication as measured by Geometric Mean Ratios (GMRs).

Time frame:
After the third and the booster vaccination.
Reported as:
Geometric mean · Ratios
Geometric Mean Ratios, One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)
RatiosB+OMV (Group I)Par+B+OMV (Group VIII)
44/76-SL > 3rd (N=157,157)80 (69 to 93)84 (72 to 97)
44/76-SL > Booster (N=59,56)24 (18 to 31)28 (21 to 36)
5/99 > 3rd (N=152,142)345 (292 to 408)417 (350 to 497)
5/99 > Booster (N=68,68)27 (21 to 35)20 (16 to 25)
NZ98/254 > 3rd (N=162,160)9.65 (8.19 to 11)8.69 (7.36 to 10)
NZ98/254 > Booster (N=129,127)12 (10 to 15)14 (11 to 17)
SecondaryPercentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (Pre-fourth Dose)

To assess the persistence of bactericidal antibodies at 12 months of age after primary vaccination - three doses of one of the seven different formulations of rMenB+OMV NZ or rMenB (no OMV) (Group I-VI and VIII) and rMenB+OMV NZ with paracetamol medication.

Time frame:
12 months (pre-fourth vaccination)
Reported as:
Number · Percentages of Subjects
Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (Pre-fourth Dose)
Percentages of SubjectsB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
44/76-SL Pre-Boost(N=69,78,74,78,71,71,74,70)55 (43 to 67)58 (46 to 69)66 (54 to 77)63 (51 to 74)45 (33 to 57)44 (32 to 56)4 (1 to 11)47 (35 to 59)
5/99 Pre-Boost(N=71,76,80,72,77,78,70,71)97 (90 to 100)100 (95 to 100)100 (95 to 100)97 (90 to 100)97 (91 to 100)99 (93 to 100)1 (0.036 to 8)100 (95 to 100)
NZ98/254 Pre-B(N=141,155,155,150,150,153,148,143)12 (7 to 19)6 (3 to 11)5 (2 to 10)3 (1 to 7)7 (3 to 12)8 (4 to 13)0 (0 to 2)11 (7 to 18)
SecondaryPercentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (One Month-post Fourth Dose)

To assess if any of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (groups I-VI and VIII) induced sufficient immune response when given to healthy toddlers at 12 months of age, as measured by percentage of subjects with SBA titer ≥ 1:5, at 1 month after the fourth vaccination.

Time frame:
1 month after fourth vaccination
Reported as:
Number · Percentages of Subjects
Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (One Month-post Fourth Dose)
Percentages of SubjectsB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
44/76-SL > Booster(N=65,73,70,75,76,71,63)100 (94 to 100)100 (95 to 100)100 (95 to 100)97 (91 to 100)100 (95 to 100)99 (92 to 100)84 (74 to 91)100 (94 to 100)
5/99 strain (N=73,77,79,72,76,74,76)100 (95 to 100)100 (95 to 100)100 (95 to 100)100 (95 to 100)100 (95 to 100)100 (95 to 100)93 (84 to 98)100 (95 to 100)
NZ98/254 (N=138,152,150,149,152,146,147,140)89 (83 to 94)89 (83 to 93)78 (71 to 84)18 (12 to 25)83 (76 to 89)88 (82 to 93)24 (18 to 32)90 (84 to 94)
SecondaryGeometric Mean Bactericidal Titers, After Primary and Booster Vaccinations (Men B at 12 Months of Age)

To assess the induction of immunological memory of three doses of meningococcal multi-component recombinant, adsorbed vaccine by comparing the serum bactericidal antibodies Geometric Mean Bactericidal Titers (GMTs) response in healthy toddlers administered the fourth dose at 12 months of age to the response in meningococcal B vaccine naive toddlers (Group VII) receiving the first dose of meningococcal multi-component recombinant, adsorbed vaccine at 12 months of age.

Time frame:
At 13 months
Reported as:
Geometric mean · Titers
Geometric Mean Bactericidal Titers, After Primary and Booster Vaccinations (Men B at 12 Months of Age)
TitersB+OMV (Group I)MenC (Group VII)
44/76-SL > Booster (N=65,75)120 (95 to 150)12 (10 to 16)
5/99 > Booster (N=73,69)1950 (1573 to 2417)41 (29 to 57)
NZ98/254 > Booster20 (16 to 24)2.2 (1.89 to 2.57)
SecondaryPercentage of Subjects With hSBA ≥1:5, First Dose of Meningococcal B Vaccine (One Month After Booster)

To assess the immune response of first dose of meningococcal multi-component recombinant, adsorbed vaccine given at 12 months of age to toddlers who previously received three doses of MenC-CRM197 vaccine as infants (group VII).

Time frame:
1 month after booster
Reported as:
Number · Percentage of Subjects
Percentage of Subjects With hSBA ≥1:5, First Dose of Meningococcal B Vaccine (One Month After Booster)
Percentage of SubjectsMenC (Group VII)
44/76-SL > Booster (N=75)84 (74 to 91)
5/99 > Booster (N=69)93 (84 to 98)
NZ98/254 > Booster24 (18 to 32)
SecondarySafety and Reactogenicity of Study Vaccines Within 7 Days After Second and Third Vaccination

To assess if any of six different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (Group II to VI, Group VIII) reduced the incidence of fever ≥ 38.5ºC (rectal) occurring within 3 days (day 1-3) following second and third vaccination and 7 days (day 1-7) following each vaccination as compared to rMenB+OMV NZ (Group I).

Time frame:
Day 1 through day 7 after second and third vaccination.
Reported as:
Number · Subjects
Safety and Reactogenicity of Study Vaccines Within 7 Days After Second and Third Vaccination
SubjectsB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
Second Vaccination (day1-3)9082763574893033
3rd vac d 1-3(N=181,179,185,183,181,180,177,179)5550361540531220
First Vaccination (day1-7)9491742460762246
Second Vaccination (day 1-7)9082773674903035
3rd vac d 1-7(N=181,179,185,183,181,180,177,179)5553381642541420
Booster d 1-7(N=155,162,169,168,168,165,164,159)8186644378688458
SecondaryNumber of Subjects With Solicited Local Reactions Within 7 Days (Day 1-7) After Each Vaccination

To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited local reactions within 7 days (day 1-7) after each vaccination.

Time frame:
Day 1 through day 7 after each vaccination.
Reported as:
Number · Subjects
Number of Subjects With Solicited Local Reactions Within 7 Days (Day 1-7) After Each Vaccination
SubjectsB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
Any Local (First Vacc)163155153123141157127137
Injection Site Tenderness (First Vacc)11411611154971214879
Injection Site Erythema (First Vacc)108999453771064573
Injection Site Induration (First Vacc)10198854886842582
Injection Site Swelling (First Vacc)5849552448601541
Any Local (Second Vacc)156156155126132156118140
Injection Site Tenderness (Second Vacc)1211169748881164785
Injection Site Erythema (Second Vacc)10411411471901044494
Injection Site Induration (Second Vacc)103105976383943879
Injection Site Swelling (Second Vacc)6461543450582152
Any Local (3rd N=181,179,185,183,181,180,177,179)151147141122130152113128
Injection Site Tenderness (Third Vacc)102987847771114266
Injection Site Erythema (Third Vacc)11010611272941016391
Injection Site Induration (Third Vacc)9792926279895580
Injection Site Swelling (Third Vacc)5656463545582947
Any Local BoostN=155,162,169,168,168,165,162,159131132149113127130133121
Injection Site Tenderness (Booster Vacc)1161071207710611210892
Injection Site Erythema (Booster Vacc)901011166780859381
Injection Site Induration (Booster Vacc)7383955666736260
Injection Site Swelling (Booster Vacc)5559693147523947
PrimaryNumber of Subjects With Fever ≥ 38.5 °C (Rectal Temperature) Within 3 Days (Day 1-3) After First Vaccination

To assess if any of six different formulations of vaccine groups (Group II to Group VI, Group VIII) reduced the incidence of fever \>=38.5C (rectal) occurring within three days (day 1-day3) following first vaccination. The analysis was done on the Safety Population.

Time frame:
Day 1 to day 3 after first vaccination.
Reported as:
Number · Subjects
Number of Subjects With Fever ≥ 38.5 °C (Rectal Temperature) Within 3 Days (Day 1-3) After First Vaccination
SubjectsB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
Number of Subjects With Fever ≥ 38.5 °C (Rectal Temperature) Within 3 Days (Day 1-3) After First Vaccination9491742460762146
SecondaryNumber of Subjects With Solicited Systemic Reactions Within 7 Days (Day 1-7) After Each Vaccination

To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited systemic reactions within 7 days (day 1-7) after each vaccination.

Time frame:
Day 1 through day 7 after each vaccination.
Reported as:
Number · Subjects
Number of Subjects With Solicited Systemic Reactions Within 7 Days (Day 1-7) After Each Vaccination
SubjectsB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
Any Systemic (First Vacc)167173175152162171136150
Change Eat. Habits (First Vacc)7687845284904166
Sleepiness (First Vacc)1201311199611711992116
Vomiting (First Vacc)2418251522261722
Diarrhea (First Vacc)5755543141494541
Irritability (First Vacc)128124128991311317997
Unus Crying (First Vacc)9510110561961086374
Rash (First Vacc)6557101045
Fever ( ≥ 38.5°C ) (First Vacc)9491742460762246
Antipyr. Med. Used (First Vacc)102949237749532166
Any Systemic (Second Vacc)168158166144156158126147
Change Eat. Habits (Second Vacc)6255585360803354
Sleepiness (Second Vacc)10510010285921097584
Vomiting (Second Vacc)1818141517201420
Diarrhea (Second Vacc)4341474039473940
Irritability (Second Vacc)130121124941171268299
Unus Crying (Second Vacc)9090847083994571
Rash (Second Vacc)49457455
Fever ( ≥ 38.5°C ) (Second Vacc)9082773674903035
Antipyr. Med. Used (Second Vacc)1009483407910539163
Any Syst (3rdN=181,179,185,182,181,180,177,179)146131132122141151106127
Change Eat. Habits (Third Vacc)4950423745602248
Sleepiness (Third Vacc)7567826477795275
Vomiting (Third Vacc)818151212131120
Diarrhea (Third Vacc)3329393134401932
Irritability (Third Vacc)1159793741041157684
Unus Crying (Third Vacc)76826247691003847
Rash (Third Vacc)164281066
Fever ( ≥ 38.5°C ) (Third Vacc)5553381642541420
Antipyr. Med. Used (Third Vacc)66605126496320153
Any Syst(BoosterN=155,162,169,169,168,165,164,159)143144139118141142142137
Change Eat. Habits (Booster Vacc)7477795270805966
Sleepiness (Booster Vacc)7690906386888580
Vomiting (Booster Vacc)61177109920
Diarrhea (Booster Vacc)3034364332302630
Irritability (Booster Vacc)1161111128611611511796
Unus Crying (Booster Vacc)7464694671827350
Rash (Booster Vacc)55828465
Fever ( ≥ 38.5°C ) (Booster Vacc)8186644378688458
Antipyr. Med. Used (Booster Vacc)84828342758092128
SecondaryNumber of Subjects With Unsolicited Adverse Events Within 7 Days (Day 1-7) After Each Vaccination

To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting unsolicited Adverse Events (AEs), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period) within 7 days (day 1-7) after each vaccination.

Time frame:
Day 1 through day 7 after each vaccination.
Reported as:
Number · Subjects
Number of Subjects With Unsolicited Adverse Events Within 7 Days (Day 1-7) After Each Vaccination
SubjectsB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
Any AE (Day 1 to 7) (First Vacc)5552513335392742
At least Possibly related AE (First Vacc)4848433027342236
Any SAE (First Vacc)01000101
Any AE D1-7 2nd N=182,181,186,184,183,180,178,1805553504136472845
At least Possibly related AE (Second Vaccination)4945453633412639
Any SAE (Second Vacc)10101000
Any AE D1-7 3rd N=182,181,186,184,182,180,177,1794059493531453539
At least Possibly related AE (Third Vacc)3452452923372936
Any SAE (Third Vacc)20201000
Any AE D 1-7Boos N=155,163,169,169,168,165,165,1613546563529303730
At least Possibly related AE (Booster Vacc)2841482323263025
Any SAE (Booster Vacc)01203000
SecondaryNumber of Subjects With Severe Adverse Events and Adverse Events Necessitating a Medical Office or Emergency Room (ER) Visit and/or Resulting in Premature Withdrawal of the Subject From the Study, Throughout the Study Period.

To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting Severe Adverse Events (SAEs) and Adverse Events (AEs) necessitating a medical office or Emergency Room (ER) visit and/or resulting in premature withdrawal of the subject from the study, throughout the study period.

Time frame:
Overall study period.
Reported as:
Number · Subjects
Number of Subjects With Severe Adverse Events and Adverse Events Necessitating a Medical Office or Emergency Room (ER) Visit and/or Resulting in Premature Withdrawal of the Subject From the Study, Throughout the Study Period.
SubjectsB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)
AE Leading to Premature Withdrawal-Primary Vacc02200121
Treatment Emergent SAEs - Primary Vacc1620122013161115
Tr E SAE Boost (N=155,163,169,169,168,165,165,161)147125159916
SecondaryNumber of Subjects With Local and Systemic Reactions Within 7 Days (Day 1-7) After Second rMenB+OMV NZ Vaccination in MenC Group

To assess the safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group VII) given at 12 and 13 months of age to toddlers who previously received three doses of Menjugate as infants.

Time frame:
Day 1 through day 7 at 13 months age.
Reported as:
Number · Subjects
Number of Subjects With Local and Systemic Reactions Within 7 Days (Day 1-7) After Second rMenB+OMV NZ Vaccination in MenC Group
SubjectsMenC (Group VII)
Injection Site Tenderness92
Injection Site Erythema84
Injection Site Induration59
Injection Site Swelling35
Change Eat. Habits (N=155)43
Sleepiness57
Vomiting8
Diarrhea18
Irritability75
Unus Crying37
Rash4
Fever ( ≥ 38.5°C ) (N=158)35
Antipyr. Med. Used (N=157)47

Adverse events

Collected over All solicited AEs and unsolicited AEs were collected from Day 1 to Day 7; serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal were collected during the overall study period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B+OMV (Group I)—16/184 (8.7%)181/184 (98.4%)
B+½ OMV (Group II)—20/184 (10.9%)183/184 (99.5%)
B+1/4 OMV (Group III)—12/189 (6.3%)186/189 (98.4%)
B (Group IV)—20/187 (10.7%)183/187 (97.9%)
½ (B+OMV) (Group V)—13/187 (7%)180/187 (96.3%)
PH2 B+OMV (Group VI)—16/185 (8.6%)180/185 (97.3%)
MenC (Group VII)—11/184 (6%)175/184 (95.1%)
Par+B+OMV (Group VIII)—15/183 (8.2%)175/183 (95.6%)
B+OMV (Group I) Booster Phase—14/155 (9%)151/155 (97.4%)
B+½ OMV (Group II) Booster Phase—7/163 (4.3%)159/163 (97.5%)
B+1/4 OMV (Group III) Booster Phase—12/169 (7.1%)162/169 (95.9%)
B (Group IV) Booster Phase—5/169 (3%)152/169 (89.9%)
½ (B+OMV) (Group V) Booster Phase—15/168 (8.9%)154/168 (91.7%)
PH2 B+OMV (Group VI) Booster Phase—9/165 (5.5%)156/165 (94.5%)
MenC (Group VII) Booster Phase—9/165 (5.5%)155/165 (93.9%)
Par+B+OMV (Group VIII) Booster Phase—14/161 (8.7%)150/161 (93.2%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)B+OMV (Group I) Booster PhaseB+½ OMV (Group II) Booster PhaseB+1/4 OMV (Group III) Booster PhaseB (Group IV) Booster Phase½ (B+OMV) (Group V) Booster PhasePH2 B+OMV (Group VI) Booster PhaseMenC (Group VII) Booster PhasePar+B+OMV (Group VIII) Booster Phase
GastroenteritisInfections and infestations1/1842/1841/1893/1871/1873/1851/1841/1832/1552/1631/1691/1691/1685/1650/1653/161
BronchitisInfections and infestations3/1842/1844/1894/1871/1872/1852/1841/1831/1551/1632/1690/1694/1681/1653/1652/161
Febrile convulsionNervous system disorders1/1841/1840/1890/1870/1870/1850/1840/1831/1551/1630/1691/1690/1681/1651/1653/161
LaryngitisInfections and infestations0/1840/1841/1891/1870/1873/1850/1840/1831/1550/1631/1693/1692/1680/1652/1651/161
Otitis media acuteInfections and infestations0/1843/1840/1890/1870/1870/1851/1840/1830/1550/1630/1690/1690/1680/1650/1650/161
Viral infectionInfections and infestations0/1841/1840/1892/1871/1870/1850/1841/1830/1550/1630/1690/1690/1681/1650/1652/161
FallInjury, poisoning and procedural complications0/1841/1840/1890/1870/1870/1850/1842/1830/1550/1632/1692/1690/1681/1650/1650/161
Gastroenteritis rotavirusInfections and infestations0/1840/1840/1891/1871/1871/1850/1841/1830/1551/1632/1690/1691/1680/1650/1650/161
BronchopneumoniaInfections and infestations1/1840/1840/1891/1870/1870/1851/1842/1831/1550/1630/1690/1691/1680/1650/1650/161
Respiratory syncytial virus infectionInfections and infestations0/1840/1841/1890/1870/1870/1850/1842/1830/1550/1630/1690/1690/1680/1651/1650/161
Most frequent other events
Showing 10 of 26
Most frequent other events
EventB+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)B+OMV (Group I) Booster PhaseB+½ OMV (Group II) Booster PhaseB+1/4 OMV (Group III) Booster PhaseB (Group IV) Booster Phase½ (B+OMV) (Group V) Booster PhasePH2 B+OMV (Group VI) Booster PhaseMenC (Group VII) Booster PhasePar+B+OMV (Group VIII) Booster Phase
IrritabilityPsychiatric disorders157/184159/184155/189139/187151/187153/185121/184137/183116/155111/163112/16986/169116/168115/165126/16596/161
Injection site painGeneral disorders150/184157/184139/189101/187131/187152/185105/184119/183121/155110/163126/16992/169111/168116/165125/16597/161
Injection site erythemaGeneral disorders151/184150/184155/189132/187131/187150/185119/184132/18397/155107/163120/16983/16989/16896/165110/16588/161
SomnolenceNervous system disorders145/184149/184146/189131/187142/187143/185113/184134/18376/15590/16390/16963/16986/16888/165100/16580/161
Injection site indurationGeneral disorders141/184139/184141/189126/187130/187130/185122/184126/18381/15590/163105/16971/16976/16881/16597/16570/161
CryingGeneral disorders122/184135/184137/18999/187125/187141/18587/184112/18374/15564/16369/16946/16971/16882/16585/16550/161
PyrexiaGeneral disorders136/184127/184122/18971/187114/187126/18562/18478/18386/15594/16370/16949/16985/16872/16592/16559/161
Eating disorderPsychiatric disorders105/184106/184104/18984/187112/187119/18563/18493/18374/15577/16379/16952/16970/16880/16572/16566/161
Injection site swellingGeneral disorders97/18494/184103/18980/18788/187100/18575/18477/18357/15563/16376/16946/16953/16857/16565/16550/161
DiarrhoeaGastrointestinal disorders84/18487/18480/18967/18780/18781/18574/18473/18331/15537/16339/16947/16934/16831/16540/16534/161

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)B+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)Total
<=18 years1881901921881911881861841507
Between 18 and 65 years000000000
>=65 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)B+OMV (Group I)B+½ OMV (Group II)B+1/4 OMV (Group III)B (Group IV)½ (B+OMV) (Group V)PH2 B+OMV (Group VI)MenC (Group VII)Par+B+OMV (Group VIII)Total
Female8891829679939872699
Male10099110921129588112808
08

Study locations

38 sites
  • Hospital Privado de Córdoba CMC SA
    Naciones Unidas 346, Cordoba X5016KHE, Argentina
  • Universidad de Chile, Av Independencia 1027
    Comuna de Independencia, Santiago, Chile
  • Consultorio Manuel Bustos
    Lo Cruzat 486, Quilicura, Santiago, Chile
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    O. Kubina 17, Boskovice 680 01, Czech Republic
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    Neklez 3, Brno 628 00, Czech Republic
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    Pernštýnská 127/l, Chlumec nad Cidlinou 503 51, Czech Republic
  • Zdravotní středisko
    Vaclavska 4186, Chomutov 430 03, Czech Republic
  • Nemocnice Decin, Detske oddělení
    U nemocnice 1, Děčín 405 01, Czech Republic
  • Fakulta vojenskeho zdravotnictvi UO
    Trebešská 1575, Hradec Králové 50001, Czech Republic
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    Masarykova 389, Humpolec 396 01, Czech Republic
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    Ruských legii 352, Jindřichův Hradec 377 01, Czech Republic
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    Hrnčířská 1401, Lipník nad Bečvou 751 31, Czech Republic
  • Oblastni nemocnice Nachod, Destske oddělení
    Purkyňova 446, Náchod 547 01, Czech Republic
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    U lékárny 306, Odolena Voda 250 70, Czech Republic
  • Prakticky lekar pro deti a dorost
    Dvouletky 54, Ostrava 700 30, Czech Republic
  • KHS Ostrava, Protiepidemické oddělení
    Na Bělidle 7, Ostrava 702 00, Czech Republic
  • Nemocnice Pardubice, Destske odděleni
    Kyjevská 44, Pardubice 532 03, Czech Republic
  • Fakultni nemocnice Bory
    E. Beneše 13, Plzeň 305 99, Czech Republic
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    Chrudimska 2a, Praha 3 130 00, Czech Republic
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    Kladenská 53, Praha 6 160 00, Czech Republic
  • Samostatna ordinace praktickeho lekare pro deti a dorost
    Velka Michalska 22, Znojmo 669 00, Czech Republic
  • Házi Gyermekorvosi szolgálat
    Honvéd u.2., Bordány 6795, Hungary
  • Medszolg 2000 Bt, 6723, Szeged, Dandár u.4
    Ányos u.4., Budapest 1031, Hungary
  • Erzsébet Kórház Gyermekosztály
    Hodmezovasarhely, dr. Imre József u.2., Hungary
  • Baby Box Bt,, 6724, Szeged, Kossuth Lajos sgt.109
    Szeged, Kossuth Lajos sgt.109, Hungary
  • Dr. Bán Mariann és Társa Bt.
    Kando Kalman u.1, Miskolc 3534, Hungary
  • Futurnest Kft
    Selyemrét u.1., Miskolc 3527, Hungary
  • Ped-Med Kft. , 3434 Mályi, Fő u.12.
    Fő u.12., Mályi 3434, Hungary
  • S.K. Sipka és Kovács Eü. Bt.
    Csongrádi sgt. 63., Szeged 6723, Hungary
  • Oszila Kft. 6723, Szeged, Debreceni u.10-14.
    Debreceni u.10-14., Szeged 6723, Hungary
  • Győriné dr. Bari Eszter egyéni vállalkozó
    Csongrad, Szentháromság tér 10, Hungary
  • Vas Megyei Markusovszky Kórház, Gyermekosztály
    Markusovszky u. 1-3, Szombathely 9700, Hungary
  • Dipartimento di Neonatologia e Terapia Intensiva Neonatale, "Ospedale dei Bambini", Presidio Ospedaliero dell'Azienda Ospedaliera Spedali Civili di Brescia
    P.le Spedali di Brescia,1, Brescia 25125, Italy
  • Dipartimento di Pediatria dell'Università degli Studi di Firenze
    Viale Pieraccini n. 24, Firenze 50139, Italy
  • Università degli Studi di Messina, Pad. NI - A.O.U. Policlinico G.Martino
    Via Consolare Valeria, 1, Messina 98125, Italy
  • Fondazione IRCCS dell'Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena di Milano
    Via Commenda, 9, Milano 20122, Italy
  • Pediatria dell'Ospedale Sacco di Milano
    Via G.B.Grossi 74, Milano 20157, Italy
  • Dipartimento di Pediatria Azienda Ospedaliera di Padova
    Via Giustiniani, 3, Padova 35128, Italy
09

References and documents

Publications

  • Viviani V, Biolchi A, Pizza M. Synergistic activity of antibodies in the multicomponent 4CMenB vaccine. Expert Rev Vaccines. 2022 May;21(5):645-658. doi: 10.1080/14760584.2022.2050697. Epub 2022 Mar 14. PubMed 35257644 ↗
  • Esposito S, Prymula R, Zuccotti GV, Xie F, Barone M, Dull PM, Toneatto D. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccin Immunother. 2014;10(7):2005-14. doi: 10.4161/hv.29218. PubMed 25424810 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Nov 2010 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2009
First posted
Jul 13, 2009
Start
Jul 2009
Primary completionActual
Nov 2010
CompletionActual
Feb 2012
Results first posted
Mar 4, 2015
Last update
Apr 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00937521
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Jul 13, 2009
Start date
Jul 2009
Primary completion
Nov 2010
Completion
Feb 2012
Results posted
Mar 4, 2015
Last update
Apr 7, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 4CMenB vaccine · Antipyretics

Start the discussion